Xtant Medical Holdings financials
$0.3591+0.93%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23.0M | $20.9M | $32.4M | $33.3M | $35.4M | $32.9M | $31.5M | $27.9M | $29.9M | $27.9M | $28.1M | $25.0M |
| Gross profit | $13.3M | $12.0M | $17.8M | $22.0M | $24.3M | $20.2M | $16.0M | $16.3M | $18.6M | $17.3M | $17.1M | $15.3M |
| Gross margin | 57.9% | 57.3% | 54.9% | 66.1% | 68.6% | 61.5% | 50.8% | 58.4% | 62.1% | 62.1% | 61.0% | 61.3% |
| Operating income | -$9.2M | -$2.9M | -$944.0K | $2.5M | $4.6M | $1.1M | -$1.9M | -$3.8M | -$2.9M | -$3.5M | -$3.8M | -$3.4M |
| Net income | -$9.4M | -$3.1M | $57.0K | $1.3M | $3.5M | $58.0K | -$3.2M | -$5.0M | -$3.9M | -$4.4M | -$4.3M | $9.2M |
| Net margin | −40.9% | −14.8% | 0.2% | 3.9% | 10.0% | 0.2% | −10.0% | −18.0% | −12.9% | −15.8% | −15.3% | 36.9% |
| Diluted EPS | $-0.07 | $-0.02 | $0.00 | $0.01 | $0.02 | $0.00 | $-0.02 | $-0.04 | $-0.03 | $-0.03 | $-0.03 | $0.07 |
| EBITDA | -$3.7M | -$2.4M | $875.0K | $3.7M | $5.8M | $2.1M | -$734.0K | -$2.7M | -$1.9M | -$2.5M | -$2.8M | -$2.5M |
| Operating cash flow | -$7.3M | -$2.1M | $5.4M | $4.6M | $1.3M | $1.3M | $665.0K | -$1.7M | -$5.1M | -$5.8M | -$915.0K | -$3.8M |
| Free cash flow | -$7.6M | -$2.3M | $5.0M | $4.2M | $910.0K | $87.0K | -$7.0K | -$3.8M | -$5.7M | -$6.5M | -$1.3M | -$4.1M |
| Diluted shares | 140.3M | 140.1M | 157.9M | 150.4M | 148.6M | 143.3M | 139.1M | 135.1M | 130.3M | 130.2M | 153.7M | 135.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $9.9M | $12.1M | $17.1M | $10.4M | $6.9M | $5.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $23.0M | $12.3M | $25.4M | $28.8M | $34.4M | $33.5M |
| Total assets | $79.7M | $78.0M | $94.1M | $106.3M | $103.5M | $95.8M |
| Total liabilities | $39.7M | $29.4M | $43.2M | $55.9M | $55.0M | $52.0M |
| Shareholders' equity | $40.0M | $48.6M | $51.0M | $50.4M | $48.5M | $43.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology